Literature DB >> 24806198

Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice.

Andrea Armani1, Francesca Cinti2, Vincenzo Marzolla1, James Morgan3, Greg A Cranston3, Antonella Antelmi1, Giulia Carpinelli4, Rossella Canese4, Uberto Pagotto5, Carmelo Quarta5, Walter Malorni6, Paola Matarrese7, Matteo Marconi8, Andrea Fabbri9, Giuseppe Rosano1, Saverio Cinti10, Morag J Young11, Massimiliano Caprio12.   

Abstract

The mineralocorticoid receptor (MR) controls adipocyte function, but its role in the conversion of white adipose tissue (WAT) into thermogenic fat has not been elucidated. We investigated responses to the MR antagonists spironolactone (spiro; 20 mg/kg/d) and drospirenone (DRSP; 6 mg/kg/d) in C57BL/6 mice fed a high-fat (HF) diet for 90 d. DRSP and spiro curbed HF diet-induced impairment in glucose tolerance, and prevented body weight gain and white fat expansion. Notably, either MR antagonist induced up-regulation of brown adipocyte-specific transcripts and markedly increased protein levels of uncoupling protein 1 (UCP1) in visceral and inguinal fat depots when compared with the HF diet group. Positron emission tomography and magnetic resonance spectroscopy confirmed acquisition of brown fat features in WAT. Interestingly, MR antagonists markedly reduced the autophagic rate both in murine preadipocytes in vitro (10(-5) M) and in WAT depots in vivo, with a concomitant increase in UCP1 protein expression. Moreover, the autophagy repressor bafilomycin A1 (10(-8) M) mimicked the effect of MR antagonists, increasing UCP1 protein expression in primary preadipocytes. Hence, we showed that adipocyte MR regulates brown remodeling of WAT through a modulation of autophagy. These results provide a rationale for the use of MR antagonists to prevent the adverse metabolic consequences of adipocyte dysfunction. © FASEB.

Entities:  

Keywords:  UCP1; adipogenesis; aldosterone; metabolic syndrome; obesity; uncoupling protein 1

Mesh:

Substances:

Year:  2014        PMID: 24806198     DOI: 10.1096/fj.13-245415

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  49 in total

Review 1.  Aldosterone Production and Signaling Dysregulation in Obesity.

Authors:  Andrea Vecchiola; Carlos F Lagos; Cristian A Carvajal; Rene Baudrand; Carlos E Fardella
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

2.  Berberine improves mesenteric artery insulin sensitivity through up-regulating insulin receptor-mediated signalling in diabetic rats.

Authors:  Feng-Hao Geng; Guo-Hua Li; Xing Zhang; Peng Zhang; Ming-Qing Dong; Zhi-Jing Zhao; Yuan Zhang; Ling Dong; Feng Gao
Journal:  Br J Pharmacol       Date:  2016-04-05       Impact factor: 8.739

Review 3.  Autophagy and Obesity-Related Lung Disease.

Authors:  Maria A Pabon; Kevin C Ma; Augustine M K Choi
Journal:  Am J Respir Cell Mol Biol       Date:  2016-05       Impact factor: 6.914

Review 4.  Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders.

Authors:  Rajesh Garg; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

5.  Mineralocorticoid vs glucocorticoid receptors: solo players or team mates in the control of adipogenesis?

Authors:  A Armani; V Marzolla; G Rosano; M Caprio
Journal:  Int J Obes (Lond)       Date:  2014-04-30       Impact factor: 5.095

Review 6.  Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease.

Authors:  Guanghong Jia; Warren Lockette; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-01-13       Impact factor: 3.619

7.  Role of Mineralocorticoid Receptor in Adipogenesis and Obesity in Male Mice.

Authors:  Daniel Ferguson; Irina Hutson; Eric Tycksen; Terri A Pietka; Kevin Bauerle; Charles A Harris
Journal:  Endocrinology       Date:  2020-02-01       Impact factor: 4.736

Review 8.  The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall.

Authors:  Guanghong Jia; Annayya R Aroor; James R Sowers
Journal:  Cardiovasc Res       Date:  2017-07-01       Impact factor: 10.787

Review 9.  Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications.

Authors:  Jonathan G Owen; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

10.  Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats.

Authors:  G Youcef; A Olivier; N Nicot; A Muller; C Deng; C Labat; R Fay; R-M Rodriguez-Guéant; C Leroy; F Jaisser; F Zannad; P Lacolley; L Vallar; A Pizard
Journal:  Br J Pharmacol       Date:  2016-04-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.